Stroke drug given during ambulance ride could boost recovery

NCT ID NCT07682922

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests whether a sublingual (under-the-tongue) tablet of edaravone dexborneol, given within 6 hours of stroke onset during transfer between hospitals, can improve functional recovery in people with acute ischemic stroke. About 1,040 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces disability at 90 days, measured by the modified Rankin Scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Edaravone dexborneol sublingual tablet
What this could lead to
If it works, this could provide a fast, easy-to-give treatment during ambulance or helicopter transfer that improves functional recovery after a stroke.
What could go wrong
This is a Phase 4 trial, but the drug is still being tested for this specific use. It may not improve outcomes, and side effects are possible. The results will need confirmation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Xinqiao Hospital and The Second Affiliated Hospital

    Chongqing, Chongqing Municipality, 400000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.